David Ferrera Calls for Greater Focus on Translational Innovation in Stroke Care

Lake Forest, CA medical device entrepreneur David Ferrera urges clinicians, engineers, and investors to prioritize disciplined execution in advancing neurovascular treatment.

LAKE FOREST, CA, March 31, 2026 /24-7PressRelease/ — David Ferrera, CEO of RC Medical and CEO of Sonorous Neuro, is raising awareness about the urgent need for more disciplined, clinically grounded innovation in the treatment of cerebral venous sinus stenosis symptomatic with pulsatile tinnitus and neuro interventional medicine. Dave is cofounder and Chairman of Infinity Neuro focusing on the treatment of ischemic and hemorrhagic stroke. With nearly 30 years in the medical device industry and more than 80 U.S. and international patents, Ferrera is advocating for a sharper focus on translational execution — turning validated clinical needs into practical, scalable solutions that improve patient outcomes.

Stroke remains one of the leading causes of death and long-term disability worldwide. According to the World Health Organization, approximately 15 million people suffer a stroke each year. Nearly 5 million die, and another 5 million are left permanently disabled. In the United States alone, someone has a stroke every 40 seconds, and every minute of untreated ischemic stroke results in the loss of an estimated 1.9 million neurons.

“Minutes matter,” Ferrera said. “If we are going to improve outcomes, we have to build devices that increase speed, reliability, and procedural confidence. Innovation only matters if it translates into real workflow improvement.”

Ferrera leads RC Medical, a venture studio that partners directly with physician-entrepreneurs in interventional radiology and neurovascular medicine. The firm funds, designs, develops, and commercializes medical devices built around clearly defined clinical problems observed inside the interventional suite.

“Most startups begin with a single idea,” Ferrera explained. “We built a repeatable system. Physicians define the problem. We validate early. We design in stages. We control burn rate. And we think about regulatory and commercialization pathways from day one.”

Through this model, RC Medical has helped form companies including Single Pass, Infinity Neuro, and Sonorous Neuro. Ferrera emphasizes that the goal is not incremental features but functional improvement.

“We do not chase novelty,” he said. “We look for devices that simplify workflow, reduce risk, or shorten procedure time. If it does not improve function in a measurable way, we pass.”

The call for translational rigor comes at a time when regulatory pathways are more complex and capital markets more selective. The U.S. Food and Drug Administration has increased scrutiny on clinical data and device safety standards, while investors are demanding clearer milestone-based progress before committing capital.

“Regulatory complexity has increased. Capital markets have tightened. Strategic buyers are more selective,” Ferrera noted. “The answer is discipline. Validate early. Define milestones. Control burn rate. Align incentives.”

Mechanical thrombectomy, one of the most significant advancements in acute ischemic stroke treatment over the past decade, demonstrates the impact of focused device innovation. Clinical trials such as MR CLEAN and DAWN have shown that rapid endovascular intervention can dramatically improve functional outcomes when performed within appropriate time windows. Yet access, speed, and device efficiency remain ongoing challenges.

“We have made progress,” Ferrera said. “But progress does not mean we are done. We still need tools that improve precision and reduce variability across operators and institutions.”

Ferrera believes that improving stroke care requires coordinated effort from multiple stakeholders — not just device companies.

“Physicians should document the problems they see every day,” he said. “Engineers should spend time in procedure rooms. Investors should fund staged development, not hype. Everyone has a role.”

He also encourages individuals outside the industry to become more informed about stroke recognition and prevention. The American Stroke Association emphasizes the importance of knowing the FAST warning signs — Face drooping, Arm weakness, Speech difficulty, Time to call emergency services. Early recognition and rapid treatment dramatically improve survival and recovery.

“Public awareness is just as important as device innovation,” Ferrera added. “Technology can only help if patients arrive in time.”

Beyond his corporate leadership, Ferrera has served as Chair of the American Heart Association’s Orange County Heart & Stroke Ball in 2020 and 2021, reinforcing his commitment to advancing cardiovascular and stroke research.

“Accountability and humility matter,” he said. “We learn from mistakes. We refine. We iterate. Big ideas succeed when execution is disciplined. Innovation is important. Translation is everything.”

Call to Action
Ferrera encourages clinicians, engineers, and investors to prioritize practical problem-solving in stroke care. Physicians can document and share unmet procedural challenges. Engineers can seek direct clinical exposure. Investors can support milestone-based development rather than speculative growth. Individuals can learn stroke warning signs, support reputable cardiovascular research organizations, and advocate for rapid emergency response systems in their communities.

Progress in stroke care will not come from slogans. It will come from disciplined collaboration.

David Ferrera is a Lake Forest, California–based engineer, entrepreneur, inventor, and advisor with nearly 30 years of experience in the medical device industry. He is CEO of RC Medical and CEO and Chairman of Sonorous Neuro. Over the course of his career, he has co-founded and led multiple neurovascular and interventional device companies from concept through commercialization and acquisition. He is the author of Innovation in Translation: How Big Ideas Really Happen (Advantage-Forbes, 2021) and holds more than 80 U.S. and international patents. Ferrera has also served as Chair of the American Heart Association’s Orange County Heart & Stroke Ball.

—
For the original version of this press release, please visit 24-7PressRelease.com here